CJC-1295/Ipamorelin is a research peptide combination pairing a GHRH (growth hormone-releasing hormone) analog with a selective GHRP (growth hormone-releasing peptide). Researchers studying the growth hormone axis often work with this pairing because CJC-1295 and Ipamorelin act on two different receptor pathways that are frequently examined together in pulsatile secretion studies. Each vial from Helix Bio is synthesized to a high purity standard and verified before it ships, with a Certificate of Analysis available for every lot. This product is manufactured strictly for laboratory research and is not intended for human or animal use.
HPLC certified
Independent analysis
Highest standard
Full traceability
CJC-1295 and Ipamorelin are two distinct synthetic peptides that are frequently studied in combination because they engage complementary pathways in growth hormone regulation. CJC-1295 is a GHRH analog, meaning its amino acid sequence is modeled after the natural growth hormone-releasing hormone produced by the hypothalamus. Ipamorelin belongs to a separate peptide class, the GHRPs, and is recognized in the research literature for its high selectivity at the ghrelin receptor with comparatively little effect on cortisol, prolactin, or appetite-related hormones relative to older GHRPs such as GHRP-6.
When supplied as a blend, both peptides are lyophilized together (or packaged as a matched pair, depending on the format ordered) so that researchers designing in-vitro or non-clinical study protocols can work with a consistent, pre-paired research reagent rather than sourcing and combining two separate vials themselves.
Each vial contains synthetic CJC-1295 and synthetic Ipamorelin in lyophilized powder form. No fillers, preservatives, or carrier proteins are added beyond what is required for stable lyophilization. Exact peptide content per vial (for example, 2mg or 5mg configurations) is listed on the individual product listing and confirmed on the batch-specific Certificate of Analysis.
This product is intended exclusively for laboratory research, including in-vitro assays, non-clinical study protocols, and educational demonstrations conducted by qualified professionals. It is not formulated, labeled, or approved for human consumption, veterinary use, or any therapeutic application.
Researchers comparing suppliers generally look for three things: verifiable purity, consistent batch quality, and clear documentation. Helix Bio structures this listing around all three. Every lot is tested before it ships, the resulting Certificate of Analysis is made available on request, and the product is labeled and packaged specifically for research use rather than marketed as a consumer wellness product. For labs already working with CJC-1295 and Ipamorelin separately, the blend format also removes a step from protocol preparation by supplying both peptides together in a single, traceable listing.
This listing is intended for:
It is not intended for individual consumers seeking a product for personal, therapeutic, or performance use.
| Specification | Details |
|---|---|
| Product Name | CJC-1295 / Ipamorelin Blend |
| Category | Growth Hormone-Releasing Hormone (GHRH) Analog + Growth Hormone-Releasing Peptide (GHRP) — Research Peptide |
| Purity | High-purity synthetic peptide, verified via HPLC prior to release |
| Appearance | White to off-white lyophilized powder |
| Storage | Store lyophilized powder frozen (-20°C) or refrigerated, protected from light and moisture, until reconstitution |
| Packaging | Sealed sterile glass vial, single-use research packaging |
| Research Use | Laboratory and non-clinical research use only — not for human or veterinary use |
| Manufacturer | Produced for Helix Bio by a contracted peptide synthesis laboratory |
| Quality | Batch-tested for purity and identity prior to release |
| Lot Testing | Certificate of Analysis (CoA) available per lot upon request |
| Country of Origin | Available upon request |
CJC-1295 and Ipamorelin are studied in the context of the growth hormone axis, receptor pharmacology, and endocrinology research. Common areas of academic and laboratory interest include:
This information is provided for educational and research context only. Helix Bio does not make claims about outcomes in humans or animals, and this product is not evaluated or approved for any therapeutic, diagnostic, or performance use.
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analog (mimics growth hormone-releasing hormone) | GHRP / ghrelin receptor agonist (selective GH secretagogue) |
| Primary Research Role | Studied for its role in stimulating the GHRH receptor pathway | Studied for selective stimulation of GH release with minimal effect on cortisol, prolactin, or appetite hormones |
| Common Forms | With DAC (extended half-life) or without DAC / Mod GRF 1-29 (shorter half-life) | Single form, known for high receptor selectivity |
| Typical Research Pairing | Frequently studied alongside a GHRP such as Ipamorelin | Frequently studied alongside a GHRH analog such as CJC-1295 |
| Molecular Class | Synthetic peptide, GHRH analog | Synthetic pentapeptide, selective GHRP |
Peptide quality is generally assessed using two complementary methods: High-Performance Liquid Chromatography (HPLC) to confirm purity, and mass spectrometry to confirm molecular identity. Helix Bio's CJC-1295/Ipamorelin blend is synthesized under controlled laboratory conditions and tested using these methods before release. The resulting Certificate of Analysis documents the batch number, purity result, and identity confirmation for that specific lot, giving researchers a paper trail they can reference in their own protocol documentation.
Because purity and stability can be affected by improper handling after the product leaves the lab, Helix Bio also packages each vial to minimize exposure to light, moisture, and temperature fluctuation during transit. Researchers who want to verify a batch independently can request the CoA before or after purchase.
Helix Bio does not publish third-party certifications that have not been independently issued, and encourages researchers to request current, batch-specific documentation rather than relying on generic purity claims.
Orders are packaged to help preserve peptide stability in transit, typically in sealed vials with protective packaging suited to domestic US shipping. Specific carrier options, delivery timeframes, and documentation (such as invoices or CoAs) can be confirmed at checkout or by contacting Helix Bio directly, as these details vary by order volume and destination.
This product is sold strictly for laboratory research use. It is not a drug, dietary supplement, food, or cosmetic, and it has not been evaluated by the FDA for safety or efficacy for any human or animal use. This product is not for human consumption. It should be handled only by qualified individuals trained in laboratory research practices, in a setting equipped for the safe handling of research chemicals. By purchasing this product, the buyer confirms they are acquiring it for legitimate research purposes and agrees not to use it for personal consumption, clinical treatment, or any purpose other than in-vitro or non-clinical research. Helix Bio makes no medical claims and does not guarantee any specific research outcome.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Check a peptide COA against the vial label, the issuing lab's own record, and supplier claims. 12 red flags, what to request, and what stays uncertain.
Eloralintide (LY3841136) research explained: AMY1R mechanism, Phase 1/2 trial data, safety signals, EloraTZP combination evidence, and current FDA status.
What bacteriostatic water contains, how it differs from sterile water and saline, where the 28-day opened-vial figure comes from, and what a COA can show.
